Table 1 Baseline demographics and characteristics
Rivoceranib + Pembrolizumab (n = 5) | |
|---|---|
Age, median (range), in years | 65 (52–72) |
Male, n (%) | 4 (80%) |
Diagnosis | |
Urothelial carcinoma of the bladder | 2 (40%) |
Gastric and gastroesophageal adenocarcinoma | 3 (60%) |
MSI– High | 0 (0%) |
Sites of metastasis | |
Lung | 2 (40%) |
Lymph Node | 2 (40%) |
Liver | 1 (20%) |
Bone | 1 (20%) |
ECOG | |
0 | 3 (60%) |
1 | 2 (40%) |
Former smoker | 2 (40%) |
History of hypertension | 3 (60%) |
Prior cancer therapy | |
Surgery | 3 (60%) |
Radiation | 4 (80%) |
Chemotherapy | 5 (100%) |
Immunotherapy | 3 (60%) |
Pembrolizumab | 2 (40%) |
Targeted | 3 (60%) |